DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Bethesda North Marriott Hotel and Conference Center

2017年10月25日 (水) 午前 7:00 - 2017年10月27日 (金) 午後 3:00

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Poster Session and Networking Reception

Speaker(s)

Nancy  Griffith, PhD

The Effects of Chiral Control on the Pharmacologic Properties of Antisense Oligonucleotides

Nancy Griffith, PhD

Wave Life Sciences, United States

Joe  Harford, PhD

A Targeted Nanocomplex that Actively Ferries Therapeutic Nucleic Acids Across the Blood-Brain Barrier

Joe Harford, PhD

SynerGene Therapeutics, Inc., United States

President & CEO

Zhong  Zhong

DMD Exon 51 Skipping Efficiency and Dystrophin Protein Restoration Induced by WVE-210201: An Investigational Stereopure ASO

Zhong Zhong

Wave Life Sciences, United States

Vice President, Biology

Petra  Kos, PhD, MPharm

miRNA-Loaded Lipid Nanoparticles for Ovarian Cancer Treatment

Petra Kos, PhD, MPharm

UT Southwestern Medical Center, United States

Postdoctoral Fellow

Meena  Meena, PhD

Preclinical Studies of WVE-120101 and WVE-12010: Investigational Stereopure ASOs for Huntington’s Disease (HD)

Meena Meena, PhD

Wave Life Sciences, United States

Senior Director

Hong  Jiang, MS

Impurity and Failure sequence Profile Change Due to Omission of the Capping Step in Synthesis of PS/PO Mixed Backbone ASOs

Hong Jiang, MS

Leal Therapeutics, United States

Scientist I

Silke  Klick, PhD

Quality Aspects of mRNA Drug Products: How Do We Control Identity, Purity, and Potency?

Silke Klick, PhD

AstraZeneca, Sweden

Regulatory Director CMC

Ruiting  Liang, PhD

A Control Strategy for GMP Manufacturing of Antisense Oligonucleotides Based on a Liquid DS Platform

Ruiting Liang, PhD

Alkermes, United States

Senior Scientist

Jennifer  Freedman, PhD

Development of a Novel Therapeutic Splice-Switching Oligonucleotide Targeting Race-Related Aggressive Prostate Cancer

Jennifer Freedman, PhD

Duke Cancer Institute, United States

Assistant Professor

Corrie L Gallant-Behm, PhD

Translatability of miR-29 PD Biomarkers from Preclinical Models to Mechanistic Proof of Concept in an MRG-201 Clinical Trial

Corrie L Gallant-Behm, PhD

Miragen Therapeutics, Inc., United States

Research Scientist III

Marcin  Kortylewski, PhD, MS

Dual Function Oligonucleotide CpG-STAT3 Inhibitor for B-Cell Lymphoma Immunotherapy

Marcin Kortylewski, PhD, MS

City Of Hope, Beckman Research Institute, United States

Professor

Mai Bailey Thayer, MS

Ultra-Sensitive Locked Nucleic Acid Hybridization-Ligation ECL ELISA for Quantitative Measurement of siRNA

Mai Bailey Thayer, MS

Amgen Inc., United States

Senior Associate Scientist

Girish R Chopda, PhD

Comparison of Subcutaneous and Intravenous Routes of Administration for Liver-Targeted RNAi Agents: Effect of PK-Modulating

Girish R Chopda, PhD

Dicerna Pharmaceuticals, United States

Associate Director, Nonclinical Development

Josh  Whisenand

Innate Immune Focused Approaches to Maximize Messenger RNA Therapeutic Activity

Josh Whisenand

TriLink BioTechnologies, United States

Brent Allen Dickinson

Pharmacokinetic and Safety Data in Monkey and Human After IV Bolus Administration of MRG-106: An Inhibitor of miR-155

Brent Allen Dickinson

Miragen Therapeutics, United States

Manager, Pharmacokinetics

Anita G Seto, PhD

Phase 1 Trial Evaluating MRG-106: A Synthetic Inhibitor of microRNA-155 in CTCL Patients

Anita G Seto, PhD

miRagen Therapeutics, United States

Associate Director, Translational Sciences

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。